FDA clears Pfizer to restart Duchenne gene therapy trial, with new safeguards

The Food and Drug Administration has cleared Pfizer to resume a late-stage trial of its experimental gene therapy for Duchenne muscular dystrophy following an investigation into certain safety concerns, including the death of a study participant, that led the regulator to suspend the program in December.